FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006329075> ?p ?o ?g. }

• W2006329075 endingPage "724" @default.
• W2006329075 startingPage "714" @default.
• W2006329075 abstract "Objective The objective of this prospective, nonrandomized study was to evaluate the immediate and long-term results of first-line chemotherapy and possible surgery in locally advanced, presumably T4 squamous cell esophageal cancer. Summary Background Data Locally advanced esophageal cancer is rarely operable and has a dismal prognosis. For this reason, neoadjuvant cytoreductive treatments are more and more frequently used with the aim of downstaging the tumor, increasing the resection rate, and possibly improving survival. Methods From January 1983 to December 1991, 163 consecutive patients with a presumedly T4 squamous cell carcinoma of the thoracic esophagus (group A) received on average 2.5 cycles (range, 1-6) of first-line chemotherapy with cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 per day, in continuous infusion from day 1 through day 5). Chemotherapy was followed by surgery when adequate downstaging of the tumor was obtained. Results Chemotherapy toxicity was WHO grade 0 to 2 in 80% of cases, but 3 toxic deaths (1.9%) occurred. Restaging suggested a downstaging of the tumor in 101 of 163 patients (62%), but only 85 patients (52%) underwent resection surgery; it was complete or R0 in 52 (32%) and incomplete or R1-2 in 33. Overall postoperative mortality was 11.7% (10 of 85), morbidity 41% (35 of 85). Complete pathologic response was documented in 6 patients, and significant downstaging to pStage I, IIA, or IIB occurred in 25 more patients. The overall 5-year survival was 11% (median, 11 months). After resection surgery, the 5-year survival was 20% (median, 16 months); none of the nonresponders survived 4 years after palliative treatments without resection (median survival, 5 months). The 5-year survival rate of the 52 patients undergoing an R0 resection was 29% (median, 23 months). Stratifying patients according to the R, pT, pN, and pStage classifications, the survival curves were comparable to the corresponding data obtained in the 587 group B patients with potentially resectable esophageal cancer who underwent surgery alone during the same period. Furthermore, the results were improved in comparison with 136 previous or subsequent patients with a locally advanced tumor who did not undergo neoadjuvant treatments (group C). In these patients, the R0 resection rate was 7%, and the overall 5-year survival was 3% (median, 5 months). Conclusion Although nonrandomized, these results suggest that in locally advanced esophageal carcinoma, first-line chemotherapy increases the resection rate and improves the overall long-term survival. In responding patients who undergo R0 resection surgery, the prognosis depends on the final pathologic stage and not on the initial pretreatment stage." @default.
• W2006329075 created "2016-06-24" @default.
• W2006329075 creator A5006953770 @default.
• W2006329075 creator A5009875698 @default.
• W2006329075 creator A5023891520 @default.
• W2006329075 creator A5031591368 @default.
• W2006329075 creator A5036178622 @default.
• W2006329075 creator A5039389370 @default.
• W2006329075 creator A5076722892 @default.
• W2006329075 creator A5090223971 @default.
• W2006329075 date "1997-12-01" @default.
• W2006329075 modified "2023-09-23" @default.
• W2006329075 title "First-Line Chemotherapy Improves the Resection Rate and Long-Term Survival of Locally Advanced (T4, any N, M0) Squamous Cell Carcinoma of the Thoracic Esophagus" @default.
• W2006329075 cites W1801371791 @default.
• W2006329075 cites W1878554291 @default.
• W2006329075 cites W1907672011 @default.
• W2006329075 cites W197442151 @default.
• W2006329075 cites W1980305385 @default.
• W2006329075 cites W2007389503 @default.
• W2006329075 cites W2012004545 @default.
• W2006329075 cites W2029081428 @default.
• W2006329075 cites W2031772203 @default.
• W2006329075 cites W2031958221 @default.
• W2006329075 cites W2038180810 @default.
• W2006329075 cites W2051784631 @default.
• W2006329075 cites W2059023406 @default.
• W2006329075 cites W2060325051 @default.
• W2006329075 cites W2063756893 @default.
• W2006329075 cites W2073929167 @default.
• W2006329075 cites W2082495445 @default.
• W2006329075 cites W2082905031 @default.
• W2006329075 cites W2083105884 @default.
• W2006329075 cites W2093658700 @default.
• W2006329075 cites W2120014319 @default.
• W2006329075 cites W2120584038 @default.
• W2006329075 cites W2144400758 @default.
• W2006329075 cites W2167805334 @default.
• W2006329075 cites W2178272638 @default.
• W2006329075 cites W2272221693 @default.
• W2006329075 cites W2276503181 @default.
• W2006329075 cites W2347198999 @default.
• W2006329075 cites W2399988932 @default.
• W2006329075 cites W2410814969 @default.
• W2006329075 cites W2411083574 @default.
• W2006329075 cites W2412945831 @default.
• W2006329075 cites W2419956285 @default.
• W2006329075 doi "https://doi.org/10.1097/00000658-199712000-00008" @default.
• W2006329075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1191144" @default.
• W2006329075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9409570" @default.
• W2006329075 hasPublicationYear "1997" @default.
• W2006329075 type Work @default.
• W2006329075 sameAs 2006329075 @default.
• W2006329075 citedByCount "69" @default.
• W2006329075 countsByYear W20063290752012 @default.
• W2006329075 countsByYear W20063290752013 @default.
• W2006329075 countsByYear W20063290752014 @default.
• W2006329075 countsByYear W20063290752016 @default.
• W2006329075 countsByYear W20063290752017 @default.
• W2006329075 countsByYear W20063290752018 @default.
• W2006329075 countsByYear W20063290752019 @default.
• W2006329075 countsByYear W20063290752020 @default.
• W2006329075 countsByYear W20063290752022 @default.
• W2006329075 crossrefType "journal-article" @default.
• W2006329075 hasAuthorship W2006329075A5006953770 @default.
• W2006329075 hasAuthorship W2006329075A5009875698 @default.
• W2006329075 hasAuthorship W2006329075A5023891520 @default.
• W2006329075 hasAuthorship W2006329075A5031591368 @default.
• W2006329075 hasAuthorship W2006329075A5036178622 @default.
• W2006329075 hasAuthorship W2006329075A5039389370 @default.
• W2006329075 hasAuthorship W2006329075A5076722892 @default.
• W2006329075 hasAuthorship W2006329075A5090223971 @default.
• W2006329075 hasBestOaLocation W20063290752 @default.
• W2006329075 hasConcept C121608353 @default.
• W2006329075 hasConcept C126322002 @default.
• W2006329075 hasConcept C141071460 @default.
• W2006329075 hasConcept C2776283816 @default.
• W2006329075 hasConcept C2776694085 @default.
• W2006329075 hasConcept C2777297899 @default.
• W2006329075 hasConcept C2777546739 @default.
• W2006329075 hasConcept C2777819096 @default.
• W2006329075 hasConcept C2778239845 @default.
• W2006329075 hasConcept C2779742542 @default.
• W2006329075 hasConcept C2994491419 @default.
• W2006329075 hasConcept C71924100 @default.
• W2006329075 hasConceptScore W2006329075C121608353 @default.
• W2006329075 hasConceptScore W2006329075C126322002 @default.
• W2006329075 hasConceptScore W2006329075C141071460 @default.
• W2006329075 hasConceptScore W2006329075C2776283816 @default.
• W2006329075 hasConceptScore W2006329075C2776694085 @default.
• W2006329075 hasConceptScore W2006329075C2777297899 @default.
• W2006329075 hasConceptScore W2006329075C2777546739 @default.
• W2006329075 hasConceptScore W2006329075C2777819096 @default.
• W2006329075 hasConceptScore W2006329075C2778239845 @default.
• W2006329075 hasConceptScore W2006329075C2779742542 @default.
• W2006329075 hasConceptScore W2006329075C2994491419 @default.
• W2006329075 hasConceptScore W2006329075C71924100 @default.
• W2006329075 hasIssue "6" @default.
• W2006329075 hasLocation W20063290751 @default.

• next